Intriguing findings strengthen ONCY's pelareorep results
November 22, 2022 - KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. KEYTRUDA in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in the trial’s primary endpoint of overall survival (OS) versus chemotherapy alone.
These Merck (MSD) findings with Keytruda in Her2-negative cancer further strengthens ONCY's findings in the Goblet and Bracelet-1 clinical trials given the Her2-negative nature of pancreatic and breast cancer and should enhance Big Pharma's interest in ONCY as an acquisition target.
https://www.merck.com/news/merck-announces-phase-3-keynote-859-trial-met-primary-endpoint-of-overall-survival-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma/
According to the National Cancer Institute - Her2-negative cancers include breast, bladder, ovarian, pancreatic and stomach cancers. Also called hman epidermal growth factor receptor 2 negative cancer.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2-negative